Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment

被引:50
作者
Adelman, Daphne T. [1 ]
Liebert, Karen J. P. [2 ]
Nachtigall, Lisa B. [2 ]
Lamerson, Michele [3 ]
Bakker, Bert [3 ]
机构
[1] Northwestern Univ, Div Endocrinol Metab & Mol Med, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA
[3] Ipsen Biopharmaceut Inc, Endocrinol Med Affairs, Basking Ridge, NJ USA
关键词
acromegaly; diagnosis; treatment; quality of life; convenience;
D O I
10.2147/IJGM.S38594
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acromegaly is a rare disease most often caused by the prolonged secretion of excess growth hormone from a pituitary adenoma. The disease is associated with multiple significant comorbidities and increased mortality. The delay to diagnosis is often long. This may be because of low disease awareness among health care professionals, the insidious onset of differentiating features, and because patients are likely to present with complaints typical of other conditions more frequently seen in primary care. Early identification of acromegaly facilitates prompt treatment initiation and may minimize the permanent effects of excess growth hormone. The primary treatment for many patients will be pituitary surgery, although not all patients will be eligible for surgery or achieve a surgical cure. If biochemical control is not achieved following surgery, other treatment options include medical therapy and radiation therapy. Improved biochemical control may only alleviate rather than reverse the associated comorbidities. Thus, lifelong monitoring of patient health is needed, with particular attention to the management of cardiovascular risk factors. It is additionally important to consider the impact of both disease and treatment on patients' quality of life and minimize that impact where possible, but particularly for chronic therapies. For the majority of patients, chronic therapy is likely to include somatostatin analog injections. In some circumstances, it may be possible to extend the dosing interval of the analog once good biochemical control is achieved. Additional convenience may be gained from the possibility of self-/partner administration of treatment or administration of treatment by a health care professional at home. Overall, it is clear that the care of patients with acromegaly requires a highly coordinated approach involving numerous specialties (eg, endocrinology, surgery, cardiology). Further, patients' needs must be at the core of management and every effort must be made to improve health care experiences and minimize treatment burdens.
引用
收藏
页码:31 / 38
页数:8
相关论文
共 44 条
[1]  
[Anonymous], 2011, DOST PRESCR INF
[2]  
[Anonymous], 2011, SAND LAR DEP PRESCR
[3]  
[Anonymous], 2011, SOM DEP PRESCR INF
[4]  
[Anonymous], 2012, SOM PRESCR INF
[5]  
[Anonymous], 2012, PARL PRESCR INF
[6]   Clinical, quality of life, and economic value of acromegaly disease control [J].
Ben-Shlomo, A. ;
Sheppard, M. C. ;
Stephens, J. M. ;
Pulgar, S. ;
Melmed, S. .
PITUITARY, 2011, 14 (03) :284-294
[7]   Morbidity after long-term remission for acromegaly: Persisting joint-related complaints cause reduced quality of life [J].
Biermasz, NR ;
Pereira, AM ;
Smit, JWA ;
Romijn, JA ;
Roelfsema, F .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (05) :2731-2739
[8]   Effectiveness and tolerability of 3-year lanreotide Autogel® treatment in patients with acromegaly [J].
Caron, P ;
Cogne, M ;
Raingeard, I ;
Bex-Bachellerie, V ;
Kuhn, JM .
CLINICAL ENDOCRINOLOGY, 2006, 64 (02) :209-214
[9]   Acromegaly [J].
Chanson, Philippe ;
Salenave, Sylvie ;
Kamenicky, Peter ;
Cazabat, Laure ;
Young, Jacques .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 23 (05) :555-574
[10]   Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease [J].
Davi, Maria Vittoria ;
Carbonare, Luca Dalle ;
Giustina, Andrea ;
Ferrari, Marcello ;
Frigo, Anna ;
Lo Cascio, Vincenzo ;
Francia, Giuseppe .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 159 (05) :533-540